Repurposed Drug May Boost Survival in Aggressive Ovarian Cancer

A drug initially developed to treat Cushing's syndrome may offer new hope for patients battling an aggressive form of ovarian cancer, according to the results of a recent clinical trial. The study found that relacorilant, a repurposed medication, has the potential to significantly improve outcomes for individuals diagnosed with platinum-resistant ovarian cancer.

Platinum-resistant ovarian cancer is a particularly challenging form of the disease, as it occurs when the cancer progresses within six months of starting platinum-based chemotherapy. This type of chemotherapy, which uses compounds containing platinum to destroy cancer cells by preventing them from dividing, is often the standard first-line treatment for ovarian cancer.

{{IMAGE_PLACEHOLDER}}